SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DRMA

Dermata Therapeutics, Inc. (NASDAQ:DRMA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.51-$0.02 (-4.23%)
 
Market cap
$2.51M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 13, 2021
Market Cap$2.51M-82.8%
Revenue (ttm)$74.14K
Net Income-$9.50M-7.4%
EPS-$3.29+88.3%
Shares Out4.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,595
Open$0.53
Previous Close$0.53
Day's Range$0.50 - $0.55
52-Week Range$0.50 - $4.66
Beta0.63
AnalystsBuy
Price Target$6.00(+1077.63%)
Earnings DateMar 31, 2027
-2.26% (1D)
No price history available.

About DRMA

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Address
3525 Del Mar Heights Road, San Diego, CA, 92130, US
Market Cap
3 million
Employees
9
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$13.09
Bought
$1.27K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From DRMA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.23%
5 Days
-15.45%
1 Month
-41.03%
6 Months
-59.56%
1 Year
-82.79%

$DRMA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DRMA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DRMA's directors and management

Net Shares Purchased by Insiders−1k−50002025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DRMA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New DRMA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DRMA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DRMA

VXFVanguard Extended Market ETF$4.21K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DRMA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Trademark registration and positive cosmetic study results support product advancement; Q3 financial update provides concrete business progress.

Recent Insider Activity

Buys
1
Sells
1
Buy Value
$1.27K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.